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Abstract
Background: Procalcitonin (PCT) testing can help in safely reducing antibiotic treatment duration in intensive care
patients with sepsis. However, the cost-effectiveness of such PCT guidance is not yet known.
Methods: A trial-based analysis was performed to estimate the cost-effectiveness of PCT guidance compared with
standard of care (without PCT guidance). Patient-level data were used from the SAPS trial in which 1546 patients
were randomised. This trial was performed in the Netherlands, which is a country with, on average, low antibiotic
use and a short duration of hospital stay. As quality of life among sepsis survivors was not measured during the
SAPS, this was derived from a Dutch follow-up study. Outcome measures were (1) incremental direct hospital
cost and (2) incremental cost per quality-adjusted life year (QALY) gained from a healthcare perspective over
a one-year time horizon. Uncertainty in outcomes was assessed with bootstrapping.
Results: Mean in-hospital costs were €46,081/patient in the PCT group compared with €46,146/patient with
standard of care (i.e. − €65 (95% CI − €6314 to €6107); − 0.1%). The duration of the first course of antibiotic
treatment was lower in the PCT group with 6.9 vs. 8.2 days (i.e. − 1.2 days (95% CI − 1.9 to − 0.4), − 14.8%).
This was accompanied by lower in-hospital mortality of 21.8% vs. 29.8% (absolute decrease 7.9% (95% CI − 13.9% to −
1.8%), relative decrease 26.6%), resulting in an increase in mean QALYs/patient from 0.47 to 0.52 (i.e. + 0.05 (95% CI 0.00
to 0.10); + 10.1%). However, owing to high costs among sepsis survivors, healthcare costs over a one-year time horizon
were €73,665/patient in the PCT group compared with €70,961/patient with standard of care (i.e. + €2704 (95% CI −
€4495 to €10,005), + 3.8%), resulting in an incremental cost-effectiveness ratio of €57,402/QALY gained. Within this time
frame, the probability of PCT guidance being cost-effective was 64% at a willingness-to-pay threshold of €80,000/QALY.
Conclusions: Although the impact of PCT guidance on total healthcare-related costs during the initial hospitalisation
episode is likely negligible, the lower in-hospital mortality may lead to a non-significant increase in costs over
a one-year time horizon. However, since uncertainty remains, it is recommended to investigate the long-term
cost-effectiveness of PCT guidance, from a societal perspective, in different countries and settings.
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Background
Procalcitonin (PCT) is a biomarker that can be used in
addition to traditional markers (i.e. C-reactive protein
(CRP)) for diagnosing and monitoring patients with
bacterial infections [1]. Findings from several rando-
mised controlled trials (RCTs) indicate that the use of a
PCT-guided antibiotic treatment algorithm (i.e. PCT
guidance) is likely to contribute to a reduction of anti-
biotic exposure in septic patients in the intensive care
unit (ICU) [2–10], without an adverse effect on health
outcomes [2, 3, 5–7, 9, 10]. In addition, a recently pub-
lished Cochrane review concluded that the use of
PCT-guided initiation and duration of antibiotic treat-
ment results in a decreased mortality risk, lower anti-
biotic consumption, and (consequently) a lower risk of
antibiotic-related side effects in patients with acute re-
spiratory tract infections [11]. Yet, the considerable
cost of PCT testing compared to other laboratory as-
says (i.e. CRP) remains an important barrier to broader
implementation. This barrier may (partly) result from
limited insight into the consequences of this PCT algo-
rithm, as both costs and health outcomes that occur
along the diagnostic and treatment pathways have not
been analysed in depth. Importantly, previous model-
ling studies into PCT guidance have suggested that it
has the potential to save costs [12–14]. However, those
studies were all based on a hypothetical patient popula-
tion instead of real-life patient outcome data, and
proved to strongly depend upon the input parameters
used. In addition, as results from cost-effectiveness
studies may not be readily transferable between
countries, it is uncertain to what extent the results
from those previous studies can be applied to the
Netherlands. In particular, as antibiotic prescription
and the duration of hospitalization are relatively low in
the Netherlands compared to other developed countries
[15, 16], this will limit the potential impact of PCT
guidance.
Recently, the Stop Antibiotics on Procalcitonin guid-
ance Study (SAPS) was performed in 1546 patients in 16
hospitals in the Netherlands to investigate the efficacy
and safety of PCT guidance in adult ICU patients with
sepsis [10]. This trial found that PCT guidance reduces
the median duration of antibiotic treatment from 7 to
5 days, and also found - unexpectedly - that this strategy
may improve survival. PCT guidance had no impact on
ICU or hospital length of stay. This trial provided exten-
sive real-life data suitable for a cost-effectiveness analysis
that allows accurate, patient-level estimates of both costs
and health outcomes with respect to PCT use in septic
ICU patients. Therefore, we used the SAPS data as the
input for a trial-based cost-effectiveness analysis in a
Dutch setting, with (on average) low antibiotic use and a
short duration of hospital stay [15, 16].
Methods
Study design and patients
The patient data were derived from the SAPS [10]. This
was a prospective, multicentre, randomised, open-label
intervention trial among patients admitted to the ICU of 4
university medical centres and 12 teaching hospitals in the
Netherlands. The medical ethical committee of the VU
University Medical Centre (Amsterdam, the Netherlands)
approved this study for all participating centres. ICU pa-
tients were eligible for inclusion if they were aged ≥
18 years and received their first dose of antibiotics for a
presumed or proven infection ≤ 24 h before trial inclusion.
Patients could participate only once. Written informed
consent was obtained from all patients or from their legal
representatives. Patients either received treatment accord-
ing to PCT guidance (PCT group, n = 761) or standard of
care (standard of care group, n = 785), based on random
allocation in a 1:1 ratio. A full description of the study de-
sign, baseline patient characteristics, and study findings
has been published previously [10, 17].
PCT was not measured in the standard of care group.
In the PCT group, PCT was measured daily until ICU
discharge or until 3 days after systemic antibiotics were
stopped, and the results were made available to the at-
tending physician. In addition, a baseline PCT measure-
ment was performed as close to initiation of antibiotics
as possible (at least within 24 h), and also made available
to the attending physician. The study protocol advised
to discontinue antibiotics if the PCT concentration had
decreased by 80% or more of its peak value, or when it
reached a value of 0.5 μg/L or less. It was left to the dis-
cretion of the attending physician whether to adhere to
this stopping advice. In the standard of care group, anti-
biotics were stopped according to local or national
guidelines, and this was also left to the discretion of
attending physicians. Except for PCT measurements, all
monitoring was similar between the PCT and the stand-
ard of care group. There was no loss to follow up. All
randomised patients were included in this health eco-
nomic evaluation.
Outcome measures and model design
A trial-based analysis was performed to estimate the
cost-effectiveness of the use of PCT guidance compared
with standard of care. The main outcome measures were
defined as the impact on the duration of antibiotic treat-
ment, in-hospital mortality, and healthcare costs. These
main outcome measures reflect the data recorded (during
the SAPS trial) on resource use and patient outcomes,
covering the period from sepsis diagnosis and initiation of
systemic antibiotic treatment until hospital discharge. In
addition, the secondary outcome measure was defined as
the incremental cost per quality-adjusted life year (QALY)
gained. This outcome measure is referred to as the
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incremental cost-utility ratio (ICUR). As the SAPS did not
collect data on quality of life (i.e. utilities) among sepsis
survivors, these were derived from a Dutch follow-up
study [18], and combined with one-year mortality rates
from the SAPS study. Short-form 36 (SF-36) scores mea-
sured at ICU discharge, hospital discharge, and 3 and
6 months after ICU discharge were converted to mean
EuroQol-5D (EQ-5D) values. These four utility scores
were extrapolated to estimate the utility one year after
ICU discharge, by fitting an exponential function over
these data using the R software [19]. An overview of the
utilities used (and accompanying references) is provided
in Additional file 1: Table S1. As these utility values (and
costs among sepsis survivors, which are described in the
next paragraph) were based on the literature and thus in-
volved additional assumptions, determination of the ICUR
was considered an additional scenario.
In addition, as the SAPS did not collect data on prod-
uctivity losses among patients with sepsis, incorporating
societal costs within this analysis would have required
making many assumptions, which would have strongly
increased the overall uncertainty in the results. However,
as current guidelines for health economic evaluations
recommend the use of a societal perspective [20], this
analysis was performed as a separate scenario. This ana-
lysis included the impact of PCT guidance on QALYs
and the costs of lost productivity (as described in more
detail in “Model inputs – costs”).
Model inputs - resource use
Data on the duration of stay on the ICU and the general
ward, antibiotic prescriptions (including the type, dur-
ation, dose, and mode of administration) and other treat-
ments administered (i.e. mechanical ventilation, dialysis,
selective digestive decontamination (SDD), and selective
oral decontamination (SOD)), were derived from the
SAPS database. Data on mean working hours were de-
rived from Statistics Netherlands for the scenario that
incorporates the estimated costs of productivity losses.
Per patient costs of diagnostic testing were calculated
based on the frequency and type of blood cultures, other
cultures, PCT tests, and (other) routine laboratory tests
that were performed (i.e. CRP, bilirubin, creatinine,
leukocyte, and thrombocyte testing). The frequency of
each, during the first 28 days of hospitalization, was ob-
tained from the SAPS database. A detailed overview of
all resource use parameters, references, and assumptions
used is provided in Additional file 1.
Model inputs – costs
Tariffs for laboratory tests, blood cultures, and other cul-
tures were derived from the Dutch Healthcare Authority
(Nederlandse Zorgautoriteit). In the current analysis, a
price of €31.71 per PCT measurement was used [21].
Tariffs for hospital stay on the ICU and general ward
(which also includes costs of hospital staff, equipment
and overheads) and costs of mechanical ventilation and
dialysis, were also obtained from the Dutch Healthcare
Authority [21, 22]. Costs of antibiotic therapy were cal-
culated by combining data from individual drug admin-
istration records from the SAPS database with their
accompanying unit costs (as published previously) [10].
All healthcare-related costs up to one year after ICU
admission (including the utilisation of hospital care,
long-term (home) care, medication, consultations with
the general practitioner, and the use of allied health care
and mental health care) were derived from literature
[23]. To ensure that these costs involved only healthcare
costs after the initial hospitalization period, the costs
after 6 months of sepsis onset were used for the purpose
of the current analysis. All costs were converted to 2017
Euros, using Dutch consumer price index levels [24].
Productivity losses were estimated using the friction cost
method. Age-dependent Dutch labour participation rates
[25, 26] were multiplied with average, gender-specific
Dutch wage rage rates [20], over a friction cost period
of 85 days in accordance with Dutch guidelines [20].
The recovery period was set at 12 weeks, which is likely
a strong underestimation of reality [27]. This analysis
also included costs of productivity losses due to prema-
ture mortality. A detailed overview of all cost parame-
ters, references, and assumptions used is provided in
Additional file 1.
Analysis
The data were analysed using R (version 3.4.1) [19].
Multiple imputation was used to handle missing values,
as this technique is known to yield more valid results
than complete case analysis [28]. This multiple imput-
ation step was performed using the package “mice” (ver-
sion 2.46) and 10 imputation sets [29]. In order to
reflect the uncertainty in cost-effectiveness outcomes,
the potential variance within the sample data should be
considered. In this regard, bootstrapping was used to in-
corporate this uncertainty and to obtain the accompany-
ing confidence intervals [30]. This bootstrap consisted of
2 stages: (1) random sampling (selection) of individual
hospitals from the 16 participating hospitals in the SAPS
study [10] and (2) random sampling (selection) of pa-
tients from the hospitals selected in step 1. This first
step was repeated until the minimum intended sample
size of 631 patients [10] was reached in both the PCT
and the control group. This two-stage bootstrapping
procedure was repeated until 10,000 samples (i.e. repli-
cated databases) had been generated.
Results for both the primary and secondary outcome
measure were presented in a cost-effectiveness plane. In
addition, to evaluate the probability that the PCT strategy
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is cost-effective, the cost-utility analysis (the secondary
outcome measure) was presented in a cost-effectiveness
acceptability curve, using willingness-to-pay (WTP)
thresholds ranging from €0/QALY to €200,000/QALY. In
the Netherlands, the WTP threshold depends on the dis-
ease burden, ranging from €20,000/QALY for low-burden
diseases, up to €80,000/QALY for high-burden diseases.
Owing to the severity of sepsis, a WTP threshold of
€80,000/QALY is most likely applicable, although the re-
sults will also be analysed using a WTP threshold of
€20,000/QALY. Similarly, the high WTP threshold is also
used in interventions for metastatic breast, lung, or colo-
rectal cancer, and for bypass surgery or percutaneous cor-
onary intervention [31–34]. In some conditions, the ICUR
may however be much higher, as illustrated by an ICUR of
€133,527 per QALY gained for chemotherapy treatment
(i.e. cetuximab) vs. best supportive care in metastatic colo-
rectal cancer [34].
As data on costs and utilities were not collected as part
of the SAPS (except for costs of antibiotic treatment),
these were based on national tariffs and published litera-
ture as described previously. To reflect the uncertainty in
these mean cost and utility estimates, a scenario was ana-
lysed in which the impact of simultaneously varying all
cost and utility parameters in the cost-effectiveness ana-
lysis was investigated using a normal distribution for costs
and a beta distribution for utilities. For costs among sepsis
survivors, the standard error was based on published lit-
erature [23]. All other parameters were varied assuming a
standard error of 10% [35].
Results
The results of this trial-based cost-effectiveness analysis
indicate that the expected in-hospital costs per patient are
€46,081/patient in the PCT group, compared with
€46,146/patient in the standard of care group. This indi-
cates an average decrease of €65/patient (95% CI − €6314
to €6107, a relative decrease of 0.14%), which can be con-
sidered negligible given the degree of uncertainty in this
incremental cost estimate. The average in-hospital mortal-
ity was 21.8% in the PCT group, compared with 29.8% in
the standard of care group, indicating a decrease of 7.9%
(95% CI − 13.9% to − 1.8%, i.e. a relative decrease of
26.6%). In addition, the duration of antibiotic use was
6.9 days in the PCT group, compared with 8.2 days with
standard of care, i.e. − 1.2 days (95% CI − 1.9 to − 0.4, i.e.
− 14.8%). When incorporating healthcare-related costs up
to one year after ICU admission, the average costs per pa-
tient increased (non-significantly) to €73,665 per patient
in the PCT group, compared with €70,961 with standard
of care, i.e. + €2704 (95% CI − €4495 to €10,005, i.e. +
3.8%). When considering the impact on QALYs, there was
an average of 0.52 QALYs in the PCT group, compared
with 0.47 QALYs in the standard of care group, i.e. + 0.05
QALYs (95% CI 0.00 to 0.10, i.e. + 10.1%), resulting in an
ICUR of €57,402/QALY gained. Assuming that annually
~ 13,000 adult ICU patients in the Netherlands are diag-
nosed with sepsis [36], the use of this PCT-guided treat-
ment algorithm could result in an annual increase in total
healthcare related costs (up to one year after ICU admis-
sion) of approximately €35 M, while saving 612 QALYs.
A detailed overview of the outcomes of the analyses
(including the 95% CIs) is provided in Table 1. The in-
cremental cost-effectiveness plane for the primary out-
come measure (i.e. costs per in-hospital death avoided)
is shown in Fig. 1 and the incremental cost-effectiveness
plane for the secondary outcome measure (i.e. costs/
QALY one year after ICU admission) is shown in Fig. 2.
Table 1 indicates that when only considering the initial
hospitalization episode, the main increase in costs in the
PCT compared with the standard of care group is
attributable to an increase in the costs of the ICU stay and
the costs of PCT testing. The main cost savings are
achieved through reduced costs of general ward stay and
mechanical ventilation. However, when considering all
healthcare-related costs up to one year after ICU admis-
sion, an increase in costs of ~ €2700 in the PCT group
(compared with standard of care) is expected. In addition,
when also including the costs of lost productivity, the dif-
ference in costs in the PCT group compared with the
standard of care group is expected to increase to ~ €2760.
When dividing the incremental costs by the incremental
QALYs, results indicate an ICUR of €57,402/QALY gained
when considering all healthcare-related costs within one
year, and an ICUR of €58,648/QALY gained when also in-
corporating societal costs.
The results of the cost-effectiveness acceptability curve
show the probability that PCT guidance (until one year
after ICU discharge) is cost-effective. This probability
was found to range from 23.5% to 95.7%, for accom-
panying WTP thresholds ranging from €0/QALY to
€200,000/QALY. For a WTP of €20,000/QALY, this
probability was 30.6%, whereas this probability was
64.4% for a WTP of €80,000/QALY (Fig. 3).
In Additional file 2, the model outcomes are shown for
the scenario in which all utilities and costs were varied
with their (assumed) standard error, including incremental
cost-effectiveness planes and the cost-effectiveness accept-
ability curve. These results indicate that incorporating the
uncertainty around utility and cost estimates does increase
the width of the 95% CIs in the PCT and the standard of
care group, although the 95% CIs of the incremental costs
are unaffected.
Discussion
The results indicate that the use of PCT guidance is ex-
pected not to affect healthcare costs during the initial
hospitalization episode, although there is considerable
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uncertainty with respect to this incremental cost esti-
mate. This is accompanied by a significant decrease in
the duration of antibiotic use and in-hospital mortality.
When considering a one-year time horizon, total
healthcare-related costs are estimated to increase by
3.8%, which is attributable to high healthcare expendi-
tures in survivors of sepsis. This is accompanied by a
(non-significant) 0.05 increase in QALYs, i.e. + 10.1%
(until one year after ICU admission), resulting in an
ICUR of €57,402/QALY gained. Incorporating the cost
of lost productivity will increase the ICUR to €58,648/
QALY gained, although uncertainty remains.
Strengths
The main strength of the current analysis is that the
majority of model inputs was derived from a large
multicentre RCT. This database had no missing values
in the effectiveness variables of interest (i.e. in-hospital
mortality and one-year mortality). In addition, the max-
imum number of missing values for the variables used in
the analysis was 5 out of 761 (i.e. 0.7%) and 4 out of 785
(i.e. 0.5%) for “length of ICU stay”, in the PCT and
standard of care groups, respectively. Consequently, the
impact of multiple imputation on the cost-effectiveness
outcomes was negligible, allowing an accurate estimation
of the cost-effectiveness of PCT guidance. Furthermore,
although (inevitably) some assumptions had to be made,
it is very unlikely that these assumptions would have af-
fected the conclusions drawn.
In addition, although the SAPS did not collect data on
quality of life (i.e. utilities), or on healthcare-related costs
up to one year after ICU discharge, the use of previously
Table 1 Overview of model outcomes
Type of parameter Parameter PCT, mean (95% CI) Standard of care, mean (95% CI) Effect, mean (95% CI)
Effectiveness outcomes
Hospital stay ICU stay, days (n) 14.6 (12.4 to 16.9) 14.3 (12.5 to 16.1) 0.3 (− 2.2 to 2.8)
General ward stay, days (n) 16.9 (13.9 to 19.6) 17.6 (14.5 to 20.8) − 0.4 (− 4.3 to 3.5)
Organ support Mechanical ventilation, days (n) 4.7 (4.0 to 5.6) 5.4 (4.5 to 6.3) − 0.6 (− 1.3 to 0.0)
Renal replacement therapy, days (n) 0.8 (0.5 to 1.1) 0.9 (0.5 to 1.3) − 0.1 (− 0.5 to 0.2)
Medication Antibiotics, days (n) 6.9 (5.6 to 8.5) 8.2 (7.0 to 9.5) − 1.2 (− 1.9 to − 0.4)
SDD and SOD (n) 4.0 (0.7 to 8.2) 4.9 (0.9 to 9.9) − 0.9 (− 2.1 to − 0.1)
Laboratory tests Cultures (n) 4.2 (2.8 to 5.9) 4.8 (3.2 to 6.5) − 0.5 (− 1.4 to 0.2)
PCT (n) 6.4 (5.7 to 7.3) 0.0 (0.0 to 0.0) 6.4 (5.7 to 7.3)
Other tests (including order tariff) (n) 14.3 (11.3 to 17.3) 14.7 (11.8 to 17.7) − 0.4 (− 2.8 to 2.1)
In-hospital mortality 21.8% (17.1% to 26.4%) 29.8% (23.5% to 36.4%) − 7.9% (− 13.9% to − 1.8%)
QALYs 0.52 (0.49 to 0.54) 0.47 (0.43 to 0.51) 0.05 (0.00 to 0.10)
Cost outcomes
Hospital stay ICU stay €32,908 (€28,109 to €38,131) €32,390 (€28,080 to €36,673) €519 (− €5227 to €6118)
General ward stay €9594 (€6218 to €12,669) €9972 (€6331 to €13,525) − €378 (− €2206 to €1300)
Organ support Mechanical ventilation €1991 (€1667 to €2369) €2259 (€1867 to €2671) − €268 (− €555 to €9)
Renal replacement therapy €362 (€244 to €500) €408 (€247 to €592) − €46 (− €217 to €116)
Medication Antibiotics €203 (€131 to €283) €237 (€168 to €317) − €35 (− €73 to €6)
SDD and SOD €127 (€32 to €226) €157 (€42 to €267) − €30 (− €64 to − €1)
Laboratory tests Cultures €109 (€72 to €151) €122 (€81 to €165) − €13 (− €34 to €6)
PCT €204 (€181 to €232) €0 (€0 to €0) €204 (€181 to €232)
Other tests (including order tariff) €584 (€484 to €677) €602 (€502 to €707) − €19 (− €96 to €56)
Total hospital costs €46,081 (€38,242 to €54,120) €46,146 (€39,383 to €53,042) − €65 (− €6314 to €6107)
Healthcare costs (follow up) €27,585 (€26,031 to €29,261) €24,815 (€22,311 to €27,056) €2770 (€136 to €5550)
Total healthcare costs (up to 1 year follow up) €73,665 (€66,065 to €81,344) €70,961 (€64,776 to €77,082) €2704 (− €4495 to €10,005)
Lost productivity €6982 (€6582 to €7370) €6923 (€6570 to €7276) €59 (− €364 to €485)
Total societal costs (up to 1 year follow up) €80,647 (€72,918 to €88,401) €77,884 (€71,604 to €84,116) €2763 (− €4491 to €10,172)
This table shows an overview of the model outcomes in terms of mean effectiveness and costs on an individual patient level. The mean model outcomes (and
accompanying 95% CIs) are shown for the procalcitonin (PCT) group and the standard of care group. In addition, the differences between these groups (and
accompanying 95% CIs) are provided
SDD selective digestive decontamination, SOD selective oral decontamination, QALY quality-adjusted life year
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published studies performed in the Netherlands [18, 23]
has likely contributed to obtaining an accurate estimate
of the long-term impact of PCT guidance.
Limitations
As data on lost productivity were not measured as part
of the SAPS, assumptions had to be made to estimate
costs of productivity losses due to the recovery period
and/or premature mortality. This could be considered as
a limitation of the analysis. However, the friction period
in the Netherlands is set at 85 calendar days, while the
recovery period after hospitalization is set at 84 calendar
days, which is likely a strong underestimation [27].
Consequently, every patient will incur the maximum
friction period of 85 days regardless of the strategy (i.e.
PCT or standard of care) and patient outcomes. The
small difference in costs of productivity loss that is ob-
served between the PCT and standard of care strategy,
Fig. 1 Incremental cost-effectiveness plane for procalcitonin (PCT) guidance compared with standard of care for costs during the hospitalisation
episode. This incremental cost-effectiveness plane shows the impact of the use of a PCT-guided antibiotic treatment algorithm, as compared to
standard of care, on the difference in in-hospital mortality and accompanying costs within this (initial) hospitalisation episode. The result is based
on 10,000 bootstrap samples
Fig. 2 Incremental cost-effectiveness plane for procalcitonin (PCT) guidance compared with standard of care for costs until one year after ICU
admission. This incremental cost-effectiveness plane shows the impact of the use of a PCT-guided antibiotic treatment algorithm, as compared to
standard of care, on the difference in quality-adjusted life years (QALYs) (until one year after ICU admission) and accompanying healthcare-related
costs within this one-year time period. In addition, the willingness-to-pay (WTP) thresholds of €20,000/QALY and €80,000/QALY are shown. The
result is based on 10,000 bootstrap samples
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however, is attributable to small differences between the
patients included in both groups, in terms of age and
gender, resulting in different hourly wage rates.
In addition, as data on resource use on the general
ward were not collected as part of the SAPS, we could
not account for patient-specific differences in resource
use on the general ward, which for example involves dif-
ferences in undergoing surgical interventions, imaging,
blood transfusion, or the use of medication. Therefore,
average costs per general-ward day were used instead
[37], incorporating costs of medical specialists, nurses,
equipment, housing, and overheads. Although this may
be considered a limitation, it is expected that the re-
source use on the general ward will not differ substan-
tially between the PCT and the standard of care group.
In addition, costs of resources used during the general
ward stay are assumed to be relatively small compared
to the high costs during the ICU stay. It is thus highly
unlikely that including these costs in more detail would
have changed the overall conclusion. Furthermore, as
approximately 50% of the infections in the SAPS were
hospital or ICU-acquired, it would have been difficult to
determine whether these costs on the general ward are
indeed related to the sepsis or to the initial reason for
hospitalisation.
All model inputs on quality of life were based on a
previous study performed by Hofhuis et al. (2008) in the
Netherlands [18]. However, this study only concerned
patients with severe sepsis who were slightly older and
who had a longer ICU and hospital length of stay com-
pared to the patients in the SAPS. The quality of life
from Hofhuis et al. is therefore likely an underestimation
of the utilities in the SAPS. In addition, the main
purpose of the current study was to investigate the im-
pact of PCT-guidance on incremental QALYs compared
to standard of care, which was mainly driven by the dif-
ference in mortality rate (as based on the results from
the SAPS). Therefore, combining the increased sur-
vival in the PCT group with a potential underestima-
tion of the quality of life of these sepsis survivors,
likely resulted in a (slight) underestimation of the
real-life impact of PCT testing on QALYs, as com-
pared with standard of care.
Results of sensitivity analysis indicate that there is
relatively large uncertainty about the impact of PCT
guidance on costs (Additional file 2). Although this com-
plicates decision-making, this uncertainty is almost inev-
itable owing to the fact that sepsis is known to be a
highly heterogeneous condition. More specifically, the
literature shows that costs rise with increasing sepsis se-
verity [38]. As the SAPS included patients with sepsis,
severe sepsis, and septic shock [10], this explains why
the duration of ICU and general ward stay varied widely
between patients. Consequently, as these parameters are
two of the main cost drivers, the uncertainty in total
costs remains considerable despite the large number of
patients included in the SAPS.
Recommendations for further research
The adherence to the advice to stop antibiotic treatment
(based on the PCT value) was only followed up within
24 h in 44% of the patients [10]. This non-adherence
may be explained by reluctance of physicians to stop
antibiotic use in patients in an unstable condition. How-
ever, over time, physicians may gain trust in PCT testing,
which may increase adherence. Consequently, the
Fig. 3 Cost-effectiveness acceptability curve. This cost-effectiveness acceptability curve shows the probability that the use of PCT-guided antibiotic
treatment is cost-effective compared to standard of care, for a willingness-to-pay threshold ranging from €0/quality-adjusted life year
(QALY) to €200,000/QALY. This analysis incorporates all healthcare-related costs over a one-year time horizon
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current study likely underestimated the impact of PCT
guidance (in terms of antibiotic use, health outcomes,
and costs). Further research is therefore warranted to
quantify the full potential impact of this PCT guidance.
Although multiple studies into the impact of PCT
guidance have already been published, it was decided
not to incorporate these into our analyses as these stud-
ies had different goals (i.e. they used a PCT algorithm to
decide to start, escalate, and/or discontinue antibiotic
treatment [2–10, 39]), and because different patient pop-
ulations were included (ranging from critically ill adults
with undifferentiated infection to surgical ICU patients
with severe sepsis) [2–10, 39]). Therefore, performing a
meta-analysis was not considered possible. In addition,
antibiotic prescription rates and the duration of hospital-
isation are relatively low in the Netherlands [15, 16].
Thus, by only using the results of this multicentre trial,
it is likely that the benefits shown in this study represent
the minimum expected benefits of PCT guidance. The
within-hospital benefits of PCT guidance are therefore
expected to be larger when performed in other coun-
tries, making it also more likely that it may be
cost-effective in these countries. However, future studies
are recommended to investigate the transferability of the
results of the current study to other countries and
settings.
Previous research has shown that shorter antibiotic
treatment duration likely decreases the incidence of re-
sistant infections and may thereby decrease costs in the
PCT group [14]. As the evidence to quantify this impact
is limited, this was not incorporated into the current
analysis, thereby underestimating the potential further
benefits of PCT guidance. Furthermore, the lower mor-
tality rate in the PCT group may incur further benefits
to society that cannot be quantified in a health economic
evaluation, including the impact on the quality of life of
relatives.
Unfortunately, the impact of PCT guidance on
long-term survival (i.e. > 1 year) and accompanying
long-term costs was not investigated as part of the SAPS
and has not been investigated previously [40]. Conse-
quently, the long-term impact of PCT guidance could
not be quantified in the current analysis. Furthermore,
as the number of studies reporting on long-term survival
and healthcare costs among sepsis survivors (in general)
is very limited, extrapolating the results of the current
study over a longer time period would make the results
highly uncertain.
Conclusions
PCT-guided antibiotic treatment in ICU patients with
sepsis is safe and reduces the duration of antibiotic use,
while the overall impact on in-hospital costs (i.e. all
healthcare-related costs occurring during the initial
hospitalisation episode) is negligible (i.e. − €65, − 0.14%).
When considering a one-year time frame, the high
healthcare-related costs occurring in sepsis survivors
may lead to a (non-significant) increase in costs of 3.8%
with PCT compared with standard of care. Within this
time-frame, the probability of PCT-guidance being
cost-effective is 64% at a WTP of €80,000/QALY, al-
though there is substantial uncertainty in the cost esti-
mates. Furthermore, a one-year time frame is too short
to capture the full potential impact of PCT guidance.
Long-term follow-up studies are required to comprehen-
sively quantify the cost-effectiveness of PCT guidance
from a societal perspective. In addition, although it is ex-
pected that the benefits of PCT guidance may be more
substantial in other countries and settings, this needs to
be investigated in future studies.
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